ZFP51 Inhibitors
Chemical inhibitors of ZFP51 can interfere with the protein's activity through various mechanisms, which involve alterations in cell cycle progression, chromatin structure, proteasome function, and kinase signaling pathways. Palbociclib, by selectively inhibiting CDK4 and CDK6, can induce cell cycle arrest, which may in turn inhibit the transcriptional activity of ZFP51 due to its potential dependence on cell cycle phases. Similarly, Alsterpaullone targets CDK1 and CDK5 among other kinases, possibly disrupting signaling processes or cell cycle progression that ZFP51 may require for its activity. Trichostatin A, as a histone deacetylase inhibitor, can alter chromatin structure, potentially affecting ZFP51's ability to access DNA or to recruit other proteins necessary for its function. MG132, by inhibiting the proteasome, can stabilize proteins that regulate ZFP51, either by direct interaction or by controlling factors that modulate ZFP51 activity.
Inhibitors that target various signaling pathways also play a role in the regulation of ZFP51. LY294002 and Wortmannin, both phosphatidylinositol 3-kinase inhibitors, can prevent post-translational modifications of ZFP51 or activation of its cofactors, which are essential for its function. U0126 and PD98059, inhibitors of MEK, can prevent the activation of the ERK pathway, possibly leading to reduced activity of ZFP51 if it relies on this pathway for full activation. Rapamycin, by inhibiting mTOR, can suppress pathways crucial for ZFP51's activation or expression. SB203580 and SP600125, which inhibit p38 MAP kinase and JNK respectively, can reduce the phosphorylation state of ZFP51, affecting its activity. Lastly, Y-27632, a ROCK inhibitor, can prevent phosphorylation events or interactions with other cofactors that are necessary for ZFP51's activity if the Rho/ROCK pathway modulates it.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib selectively inhibits cyclin-dependent kinases CDK4 and CDK6. Since ZFP51 is a transcription factor, its activity can be dependent on the cell cycle. Inhibition of CDK4/6 by Palbociclib can lead to cell cycle arrest, thereby inhibiting the function of ZFP51 as it may not be able to exert its transcriptional activity effectively during cell cycle arrest. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. ZFP51, being a zinc finger protein, may bind to DNA and interact with histones. By inhibiting histone deacetylases, Trichostatin A can cause changes in chromatin structure, potentially inhibiting ZFP51's ability to bind DNA or recruit other proteins required for its function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor. ZFP51 may be regulated by proteasomal degradation. By inhibiting the proteasome, MG132 can increase the levels of proteins that may functionally inhibit ZFP51 or its binding partners, indirectly inhibiting its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphatidylinositol 3-kinase inhibitor. If ZFP51 activity is regulated by PI3K signaling, LY294002 could inhibit this pathway, leading to the functional inhibition of ZFP51 by preventing its post-translational modifications or the activation of its cofactors. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor. ZFP51's function could be regulated by the ERK/MAPK pathway. By inhibiting MEK, U0126 could prevent the activation of ERK, which may be necessary for the full activational capabilities of ZFP51, leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mammalian target of rapamycin (mTOR). If the activity or stability of ZFP51 is dependent on mTOR signaling, inhibition by Rapamycin would suppress ZFP51's function by inhibiting pathways necessary for its activation or expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. ZFP51 could be functionally regulated by p38 MAPK signaling. Inhibition of this pathway by SB203580 could lead to reduced phosphorylation and activation of ZFP51, resulting in its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 can prevent the activation of ERK, potentially inhibiting the function of ZFP51 if the protein's activity is regulated by this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the c-Jun N-terminal kinase (JNK). Inhibition of JNK could affect the phosphorylation state of ZFP51 if it is a downstream target, resulting in its functional inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, similar to LY294002. It can inhibit the function of ZFP51 by blocking the PI3K pathway which may be crucial for ZFP51's activation or stability. | ||||||